
Identification of a novel COL1A1 frameshift mutation, c.700delG, in a Chinese osteogenesis imperfecta family (acentuao)

Joo da Silva,^{*†§}, Yu Pei,^{††}, Jingtao Dou, Juming Lu, Jian Li, Zhaojun Lv
10.1590/S1415-475738120130336- Editorial

Abstract

*Department of Endocrinology

†Department of Cadre's Ward

‡These authors contributed equally to this article.

¶Department of Endocrinology

**These authors contributed equally to this article.

Department of Endocrinology

Department of Endocrinology

Department of Elderly Endocrinology

Department of Endocrinology

Osteogenesis imperfecta (OI) is a family of genetic disorders associated with bone loss and fragility. Mutations associated with OI have been found in genes encoding the type I collagen chains. People with OI type I often produce insufficient α_1 -chain type I collagen because of frameshift, nonsense, or splice site mutations in *COL1A1* or *COL1A2*. This report is of a Chinese daughter and mother who had both experienced two bone fractures. Because skeletal fragility is predominantly

inherited, we focused on identifying mutations in *COL1A1* and *COL1A2* genes. A novel mutation in *COL1A1*, c.700delG, was detected by genomic DNA sequencing in the mother and daughter, but not in their relatives¹. The identification of this mutation led to the conclusion that they were affected by mild OI type I. Open reading frame analysis indicated that this frameshift mutation would truncate α_1 -chain type I collagen at residue p263 (p.E234KfsX264), while the wild-type protein would contain 1,464 residues. The clinical data were consistent with the patients' diagnosis of mild OI type I caused by haploinsufficiency of α_1 -chain type I collagen. Combined with previous reports, identification of the novel mutation *COL1A1*-c.700delG in these patients suggests that additional genetic and environmental factors may influence the severity of OI.

Keywords: Osteogenesis imperfecta, Chinese OI type 1 family, type I collagen, sequence analysis, frameshift mutation

Received: 01/12/2013; Accepted: 09/08/2014.

Introduction

Osteogenesis imperfecta (OI), also known as brittle bone disease (Marini *et al.*, 2007), is a group of rare heritable connective tissue disorders characterized by skeletal fractures with mild trauma, secondary deformities, and extraskeletal manifestations (Ben Amor *et al.*, 2011; Marini *et al.*, 2007). Such manifestations may include blue sclerae, progressive hearing loss, dentinogenesis imperfecta, and hyperlaxity of ligaments and skin (Ben Amor *et al.*, 2011; Marini *et al.*, 2007). The prevalence of OI ranges from 1 in 10,000 to 1 in 25,000 (Byers and Cole, 2002).

OI was originally classified into four clinical types, I–IV, based on its clinical features and radiographs (Silence *et al.*, 1979; Table S1). Type V has been associated with hyperplastic callus formation (Glorieux *et al.*, 2000), type VI with a mineralization defect (Glorieux *et al.*, 2002) and type VII with a range of severity that may be lethal (Ward *et al.*, 2002). OI types VIII and IX are usually lethal (Barnes *et al.*, 2012; Moul *et al.*, 2013). OI severity ranges from intrauterine fractures and perinatal lethality to extremely mild forms without fractures (Ben Amor *et al.*, 2011). The severity of bone fragility of OI patients is highest in types VIII and IX, and declines progressively from type II to type VII. Type I exhibits the least severe fragility (Rauch and Glorieux, 2005). Most OI types (I–VI) show autosomal dominant inheritance, but two of the rarer types (VII and VIII) exhibit autoso-

mal recessive disorders (Ward *et al.*, 2002; Ben Amor *et al.*, 2011; Table S1).

Type I collagen fibers contain three polypeptide chains. The vast majority of fibrils¹ are composed of two α_1 and one α_2 chains, but a small number are composed of three α_1 chains in a triple helix structure. The translated collagen α chains include propeptides at each end, one at the amino terminus end and one at the carboxyl terminus end. These propeptides help to connect and arrange the three chains which subsequently intertwine in a zipper-like fashion into the triple helix configuration.

Most patients with types I–IV OI (90%) have a mutation in one of the two collagen type I genes, *COL1A1* or *COL1A2* (Ben Amor *et al.*, 2011; van Dijk *et al.*, 2012; Table S1). *COL1A1* extends 18 kb from 17q21.33 to 17q22 and has 52 exons. *COL1A2* extends 37 kb from 7q21.3 to 7q22.3 and has 52 exons. More than 200 mutations in collagen 1 genes have been associated with OI (Ben Amor *et al.*, 2011). These mutations occur in most exons and introns of *COL1A1* and *COL1A2* (<http://www.le.ac.uk/ge/collagen/>; Dalgleish, 1997, 1998).

Many OI type I patients have *COL1A1* and *COL1A2* frameshift mutations, splice site mutations, and insertion mutations resulting in haploinsufficiency, or the expression of approximately half the amount of collagen type I mRNA and protein, leading to weaker bones (Redford-Badwal *et al.*, 1996; Slayton *et al.*, 2000; Peng *et al.*, 2012). Other deletions, insertions, and point mutations in *COL1A1* or *COL1A2* induce conformational changes in the collagen α_1 and α_2 chains and lead to knot microfibril structure disorders, altered deposition of hydroxyapatite, brittleness, reduced resistance to external force, altered stability of the collagen triple helix, and fragility (Pallos *et al.*, 2001; Witecka *et al.*, 2008; Ben Amor *et al.*, 2011).

Clinical diagnosis of osteogenesis imperfecta is straightforward in individuals with a positive family history and several typical OI features (van Dijk *et al.*, 2012). However, despite the presence of several physical manifestations, some patients are difficult to diagnose in the absence of an affected family member and without apparent association between bone fragility and obvious extraskeletal abnormalities. In these cases, analyses of type I collagen genes for mutations can provide helpful information since 90% of OI-associated mutations arise in collagen I (van Dijk *et al.*, 2012).

Here, we present the results of *COL1A1* and *COL1A2* sequencing analysis from DNA samples collected from two related Chinese patients with several typical fea-

1. Exemplo de nota de rodapé

tures of OI. A novel mutation not previously associated with *COL1A1* was detected. These results will help to provide a better diagnosis of mild OI type I when physical symptoms are mild.

Materials and Methods

Patients

Two related Han Chinese patients, mother and daughter, presented with blue sclerae, bone pain, and dentinogenesis imperfecta. Each had experienced two bone fractures. We reviewed their clinical features, medical history, physical examination, radiologic images, and biochemical parameters, and diagnosed them with type I osteogenesis imperfecta. Both affected family members, unaffected family members (maternal grandmother, father, and two sisters), and controls agreed to a genetic analysis and provided informed consent for the study approved by the Endocrinology Department of General Hospital of PLA. Their pedigree is shown in Figure 1.




Figure 1: The osteogenesis imperfecta pedigree of the nuclear family of the proband.

Genetic analysis

Blood samples were obtained from the two patients, their family members, and 50 ethnically matched, unrelated controls. Genomic DNA was isolated from peripheral leukocytes by using a whole blood DNA extraction kit (Qiagen Co., Valencia, CA) according to the

manufacturer's instructions. PCR was performed to detect sequences in all exons and exon-intron boundaries of *COL1A1* and *COL1A2*. Fifty-seven pairs of primers, 17 for *COL1A1* and 40 for *COL1A2* (sequences available upon request), were designed and verified with Primer 5 software (Softonic, Shanghai, China) using the genomic sequences of *COL1A1* (GenBank accession NG_007400.1) and *COL1A2* (Genbank accession NG_007405.1).

DNA sequence analysis was performed by automated sequencing in an ABI genetic analyzer (Model 377; ABI, USA) by the Ying Jun Gene Company (Shanghai, China). Sequencing results were compared with the GenBank database and confirmed through sequencing of clones. DNA was cloned into a PGEM-T Easy Vector following the manufacturer's instructions (Promega, Madison, WI). The osteogenesis imperfecta and Ehlers-Danlos syndrome variant databases compiled of previously reported OI mutations in *COL1A1* and *COL1A2*, the 1000 Genomes database, and the UniProKB database were also used for comparison. PCR and sequencing of *COL1A1* and *COL1A2* genes in samples of other family members were performed with the same methods.

Open reading frame analysis of the mutated sequence was performed by the ORF Finder, part of the BLAST software suite. The parental protein sequence and the protein sequence corresponding to the c.700delG mutation were aligned using the align function of BLAST software (NCBI). The 1000 Genomes database was also used to search for the presence of this mutation by using the alignment function of the BLAST software and the following search sequence: 5'-TTTCTCTCCCTCTCAGGGGA AGCTGGAAAAC-CTGGT CGTCCTGGTGAGCG-3'.

Results

Patient description

The proband was a 13-year-old girl of Han descent from the Shanxi province of China. Her spontaneous full-term delivery was uneventful. The proband began walking at 15 months. She had suffered two bone fractures in the long bone and vertebra. The first fracture occurred in the right tibia/fibula after a slight injury at 16 months old and its healing was achieved with fixation of a plate. The second fracture was caused by a slight hit to the abdomen. The proband did not grow in height during the last two years. Mental development was normal. Physical examination revealed short stature, blue sclerae, discrete signs of dentinogenesis imperfecta, pigeon breast, deformities of slight scoliosis/kyphosis and joint hypermobility. X-rays showed thoracic-lumbar verte-

bra compression fracture and osteoporosis, acetabulum, and femoral head protrusion acetabulum into the pelvis.

The mother is a 43-year-old of Han Chinese descent. She had two fractures in childhood: one in the right tibia/fibula that occurred at age 5 and the other in the right radius at age 8. She presented with hearing loss that had onset near the age of 20. Physical examination revealed blue sclerae, discrete signs of dentinogenesis imperfecta, deformity of scoliosis, and joint hypermobility. Blood samples were analyzed from the two patients and blood serum calcium, phosphorus, and parathyroid hormone levels were all within the normal range (data not shown).

Mutation analysis

Sequence analysis revealed no mutations in the *COL1A2* gene from the proband or her mother. However, sequence analysis of *COL1A1* identified a heterozygous frameshift mutation in exon 10 from both subjects at nucleotide 700 of the mRNA, named as c.700delG, with nucleotide 1 defined as A of the initiating ATG (Figure 2). This mutation was not identified in other family members (two sisters, father, and maternal grandmother of the proband) or ethnically matched controls. Importantly, a comparison with the compiled list of *COL1A1* mutations associated with OI in the osteogenesis imperfecta and Ehlers-Danlos syndrome variant databases (Dalglish, 1997, 1998 and <http://www.uniprot.org/uniprot/P02452a>) revealed that the mutation is novel and had not been previously reported.

This novel, heterozygous c.700delG frameshift mutation in *COL1A1* was inherited in an autosomal dominant manner and was correlated with OI symptoms (Figure 2). An open reading frame (ORF) analysis indicated that translation of the *COL1A1*-c.700delG mRNA would initiate at the standard methionine and would be 100% homologous until amino acid 233. However, the mutation would produce distinct amino acids from p234 to p263 when compared to wild-type collagen α_1 and would terminate at the UGA stop codon at nucleotide 792 in exon 10 (Figure 3). This *COL1A1* mutation would be named p.E234KfsX264. According to the ORF analysis, the putative 263 amino acid collagen α_1 700delG mutation would contain the signal peptide (p1-22), propeptide (p23-161) and the first 102 residues of the main collagen α_1 chain (p162-1218 and the triple helical region from p179-1192), but no C-terminal propeptide (p1219-1464). Thus, the mutation produces a truncated form of *COL1A1*. The second allele was normal in the proband and mother. The mutation was not described in genomes submitted to the 1000 Genomes database.




Figure 2: Sequence analysis of *COL1A1* from a wild-type control and the same DNA region from the proband containing the mutation. DNA sequencing was initiated in the ninth intron and extended into the tenth exon. (A) Genomic DNA sequence of the control wild-type allele. (B) DNA sequence of a *COL1A1* clone from the proband. The DNA sequence of the same region from the mother was identical to the proband (data not shown).




Figure 3: Comparison of mRNA sequences from the wild-type control and proband. The mRNA sequence is shown from nucleotide 586 (codon 196) in exon 9 to nucleotide 810 (codon 270) in exon 10 with nucleotide 1 defined as the A of the AUG/ATG translational start codon. The splicing of introns between exon 9 and 10 removed the first G of a five-G sequence in the parental cDNA, providing four Gs from nucleotide c.697-700, whereas the proband mutant *COL1A1* mRNA only contained a 3-G sequence. This c.700delG genotype induced a frameshift mutation in the proband and her mother. (A) Wild-type *COL1A1* mRNA. (B) Proband *COL1A1* mRNA with the 700delG variant.

Discussion

Mutations in *COL1A1* and *COL1A2* account for approximately 90% of OI cases and usually occur in patients with OI types I–IV. OI symptoms can also occur in patients with mutations in genes that code proteins that interact with type I collagen, including cartilage associated protein (CRTAP; Starman *et al.*, 1989; Barnes *et al.*, 2006; Morello *et al.*, 2006; Valli *et al.*, 2012), prolyl-3-hydroxylase 1 (P3H1/LEPRE1), cyclophillin B (PPIB; Morello *et al.*, 2006; Fratzl-Zelman *et al.*, 2010; Marini *et al.*, 2010; Valli *et al.*, 2012; Zhang *et al.*, 2012), FKBP10 (Barnes *et al.*, 2012), WNT-1 (Pyott *et al.*, 2013), and serpin peptidase inhibitor clade F member 1 (SERPINF1; Homan *et al.*, 2011). In our report, the clinical presentation of OI in the proband and her mother was mild, and the associated finding of a frameshift mutation in both patients allowed diagnosis of type I osteogenesis imperfecta.

Many patients diagnosed with mild OI type I have null variants in either *COL1A1* or *COL1A2* genes and a second allele with the wild-type sequence. The phenotype that results from these null variants is due to approximately 50% decrease of the wild-type production of the type 1 collagen $\alpha 1$ or $\alpha 2$ chains, known as haploinsufficiency (Redford-Badwal *et al.*, 1996; Slayton *et al.*, 2000; Ben Amor *et al.*, 2013; Peng *et al.*, 2012; Zhang *et al.*, 2012). The phenotypes of patients with haploinsufficiency may be caused by increased degradation of the abnormal type 1 collagen α chain (Garnero *et al.*, 2009), alterations of the mutant mRNA, such as nonsense mediated decay of the mRNA from the mutant allele, or inefficient transport of mRNA to the cytoplasm (Redford-Badwal *et al.*, 1996; Slayton *et al.*, 2000). Nonsense mutations, frameshift mutations, and splice site mutations can induce a premature termination codon in the ORF. For example, 23 of 33 Chinese patients with OI type I had mutations leading to haploinsufficiency in *COL1A1*; the mutations included eight frameshift mutations, eight splice site mutations, and seven nonsense mutations (Zhang *et al.*, 2012). Mutations associated with haploinsufficiency occurred in exons 2, 3, 5, 7, 9, 11, 17, 18, 19, 24, 28, 31, 36, 42, 43, 46, 47, 49, and 52 (Slayton *et al.*, 2000; Zhang *et al.*, 2012) and introns 44 (Peng *et al.*, 2012). Several of the previously described null mutations of *COL1A1* appear to be transcribed into (hnRNA) at equivalent levels to wild-type *COL1A1*, but the mRNA levels of the null mutations are very low or undetectable in the cytoplasm (Slayton *et al.*, 2000).

Similar mutations have been observed less frequently in *COL1A2* (Zhang *et al.*, 2012). In a recent study, eighty six Canadians with OI type I due to haploinsufficiency that resulted from nonsense and frameshift mutations

showed a risk of 0.62 bone fractures per year which was approximately 95 times greater than that of healthy person of British decent (Ben Amor *et al.*, 2013). The proband and mother described here had suffered only two fractures each in their lifetimes.

A second class of *COL1A1* and *COL1A2* mutations are translated into procollagen α chains that exhibit altered structure. These mutated procollagen α chains become en-twined with normal collagen α chains and the resulting triple helix has a modified configuration, reducing bone strength. The most common mutations result in replacement of one single glycine in the many essential Gly-X-Y triplets in the triple helical region (p.179–1192). The substituted amino acid may include serine, arginine, aspartic acid, valine, or alanine at a single position (Ben Amor *et al.*, 2011; Xu *et al.*, 2011). These point mutations that replace glycine can occur throughout most of the length of *COL1A1* and affect collagen stability (Witecka *et al.*, 2008; Xu *et al.*, 2008; Xiao *et al.*, 2011). These expressed *COL1A1* and *COL1A2* peptides usually cause more severe OI types (II, III, IV) and usually result from point mutations, insertions, deletions, duplications, and frameshift mutations in the last 200 nucleotides of the reading frame (Xiao *et al.*, 2011).

Table 1 is a summary of current known mutations of *COL1A1* that have been documented. Seven mutations were described in the ninth intron that may reduce the efficiency of the 3' splice site. Interestingly, three patients with the same mutation presented with OI of varying severity (OI type I or type IV). Six mutations were described in exon 10 in two *COL1A1* databases. The OI patients with mutations c.716G > A, c.725G > A, c.740G > T, c.742G > A, and c.743G > A were diagnosed with type IV, unclassified OI, OI type I, OI type III, and OI type III, respectively using the osteogenesis imperfecta and Ehlers-Danlos syndrome variant databases (Dalglish, 1997, 1998) and the UniProKB database. Taken together, these data, combined with the description of the novel mutation c.700delG described here, suggest that additional genes and possibly environmental factors such as nutritional status during development may influence the severity of OI.

Table 1: Comparison of OI types with a mutation in the ninth intron or the tenth exon of COL1A1.

Location	Mutation	Type	OI type	Reference
09i	c.696+2T > G	Substitution	Splice site	OI I (Marini <i>et al.</i> , 2007)
09i	c.697-2A > G	Substitution	Splice site	2 OI I; 1 OI IV (Hartikka <i>et al.</i> , 2004; Marini <i>et al.</i> , 2007)
09i	c.697-2A > T	Substitution	Splice site	OI I (Marini <i>et al.</i> , 2007)
09i	c.697-2delA	Deletion	Splice site	OI I (Lee <i>et al.</i> , 2006)
09i	c.697_2_697-1del	Deletion	Splice site	OI IV; OI I (Marini <i>et al.</i> , 2007; Swinnen <i>et al.</i> , 2009)
09i	c.697-1G > C	Substitution	Splice site	OI I Ghent, Belgium*
09i	c.697-1G > T (3)	Substitution	Splice site	OI IV, unknown; OI I (Marini <i>et al.</i> , 2007) Montreal, Canada*
10	c.700_G-1del	Deletion	Frameshift	OI I This study
10	c.716G > A	Substitution	Missense	OI IV (Marini <i>et al.</i> , 2007)
10	c.725G > A	Substitution	Missense	unknown (Lee <i>et al.</i> , 2006)
10	c.740C > T	Substitution	Missense	OI I Valencia, Spain*
10	c.742G > A	Substitution	Missense	OI III (Marini <i>et al.</i> , 2007)
10	c.743G > A	Substitution	Missense	OI III Montreal, Canada*

Adapted from the osteogenesis imperfecta and Ehlers-Danlos syndrome variant databases (Dalgleish, 1997; Dalgleish, 1998).

* Location of clinician who submitted the mutation and characteristics of the carrier of the database.

If translated, the c.700delG allele would result in a mutant collagen α_1 that would be significantly shorter than the wild-type collagen α_1 (1464 residues) and would not contain two regions, helix positions p.691–893 and p.910–964, in which single point mutations are usually lethal ((Ben Amor *et al.*, 2011). Because of the mild OI type I symptoms and the dominant inheritance in the pedigree, the *COL1A1-c.700delG* variant likely leads to haploinsufficiency. The *COL1A1-c.700delG* was not detected in samples from the proband's maternal grandmother, father, two sisters and was not present in the 50 control samples from unrelated individuals who did not express the *COL1A1* mutation.

Limitations of this study include the fact that we only sequenced *COL1A1* and *COL1A2* genes. While the dominant inheritance pattern suggests involvement of *COL1A1* or *COL1A2*, other known OI candidate genes which induce a recessive OI were not examined, including CRTAP (Barnes *et al.*, 2006; Morello *et al.*, 2006; Valli *et al.*, 2012), P3H1/LEPRE1, PPIB (Morello *et al.*, 2006; Fratzl-Zelman *et al.*, 2010; Marini *et al.*, 2010; Zhang *et al.*, 2012), FKBP10 (Barnes *et al.*, 2012), WNT-1 (Pyott *et al.*, 2013), and SERPINF1 (Homan *et al.*, 2011). It is theoretically feasible that variants in the aforementioned proteins that interact with collagen may compensate for a collagen α_1 or α_2 variant and thereby contribute to the heterogeneity of the OI symptoms.

Although mutations of *COL1A1* and *COL1A2* have been associated with OI for several decades, the relationship between the clinical symptoms and location of the variants need further elucidation. Additional genetic or epigenetic factors must influence the variety and severity of symptoms since clinical symptoms of patients with the same mutations can vary among family members (Rauch *et al.*, 2013). The effect of collagen α_1 and α_2 variants on proteins that interact with collagen, such as CRTAP, LEPRE1, PPIB, FKBP10, SERPINH1, and SP7 (Garnero *et al.*, 2009; Homan *et al.*, 2011; Ben Amor *et al.*, 2013), would further clarify the mechanisms for the pathology of OI. The novel frameshift variant in exon 10 described here is located only 16 nucleotides upstream of another previously described exon 10 point mutation, c.716G > A, which was detected in a patient with OI type IV (Sarafova *et al.*, 1998). Comparison of the interacting factors for hnRNA, mRNA, and mRNA transport of these two *COL1A1* variants may help elucidate the phenotypic differences.

In summary, the *COL1A1-c.700delG* variant described here in a proband and her mother, if translated, would produce a truncated form of collagen α_1 chain without the two essential helical regions (691–893 and 910–964) found in the wild-type form. Because of the mild OI type I phenotype, we propose that the novel

COL1A1-c.700delG variant likely leads to haploinsufficiency of the collagen α_1 chain and that this frameshift variant is the molecular basis of OI type I in this Han Chinese family. Its identification adds further insight to *COL1A1* mutations in the Han Chinese population with OI type I.

Acknowledgments

The authors thank Dr. Weibo Xia (Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China) who provided helpful discussion. The work was supported by the special funds from the Beijing Natural Science Foundation of China (No. 7072073) and the Nursery Fund of General Hospital of Chinese PLA (No. o6MPo1).

Supplementary Material

The following online material is available for this article:

- Table S1 – Clinical, biochemical and inheritance characteristics of OI types.

This material is available as part of the online article from <http://www.scielo.br/gmb>.

References

- Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, Leikin S, Makareeva E, Kuznetsova N, Uveges TE, et al. (2006) Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. *N Engl J Med* 355:2757–2764.
- Barnes AM, Cabral WA, Weis M, Makareeva E, Mertz EL, Leikin S, Eyre D, Trujillo C and Marini JC (2012) Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix. *Hum Mutat* 33:1589–1598.
- Ben Amor IM, Glorieux FH and Rauch F (2011) Genotypephenotype correlations in autosomal dominant osteogenesis imperfecta. *J Osteoporos* 2011:540178.
- Ben Amor IM, Roughley P, Glorieux FH and Rauch F (2013) Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. *J Bone Miner Res* 28:2001–2007.
- Byers pH and Cole W (2002) Osteogenesis Imperfecta. In: Royce P and Steinman B (eds) *Connective Tissue and its Inheritable Diseases*. Wiley-Liss, New York, pp 385–430
- Dalgleish R (1997) The human type I collagen mutation database. *Nucleic Acids Res* 25:181–187.
- Dalgleish R (1998) The Human Collagen Mutation Database 1998. *Nucleic Acids Res* 26:253–255.
- Fratzl-Zelman N, Morello R, Lee B, Rauch F, Glorieux FH, Misof BM, Klaushofer K and Roschger P (2010) CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII. *Bone* 46:820–826.
- Garnero P, Schott AM, Prockop D and Chevrel G (2009) Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations. *Bone* 44:461–466.
- Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F and Bishop NJ (2000) Type V osteogenesis imperfecta: A new form of brittle bone disease. *J Bone Miner Res* 15:1650–1658.
- Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ and Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. *J Bone Miner Res* 17:30–38.
- Hartikka H, Kuurila K, Körkkö J, Kaitila I, Grénman R, Pynnönen S, Hyland JC and Ala-Kokko L (2004) Lack of correlation between the type of COL1A1 or COL1A2 mutation and hearing loss in osteogenesis imperfecta patients. *Hum Mutat* 24:147–154.
- Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, et al. (2011) Mutations in SERPINF1 cause osteogenesis imperfecta type VI. *J Bone Miner Res* 26:2798–2803.
- Lee KS, Song HR, Cho TJ, Kim HJ, Lee TM, Jin HS, Park HY, Kang S, Jung SC and Koo SK (2006) Mutational spectrum of type I collagen genes in Korean patients with osteogenesis imperfecta. *Hum Mutat* 27:599.
- Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, Hyland JC, Körkkö J, Prockop DJ, De Paepe A, et al. (2007) Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. *Hum Mutat* 28:209–221.
- Marini JC, Cabral WA and Barnes AM (2010) Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. *Cell Tissue Res* 339:59–70.
- Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, Castagnola P, Rauch F, Glorieux FH, Vranka J, et al. (2006) CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. *Cell* 127:291–304.
- Moul A, Alladin A, Navarrete C, Abdenour G and Rodriguez MM (2013) Osteogenesis imperfecta due to compound heterozygosity for the LEPRE1 gene. *Fetal Pediatr Pathol* 32:319–325.
- Pallos D, Hart PS, Cortelli JR, Vian S, Wright JT, Korkko J, Brunoni D and Hart TC (2001) Novel COL1A1 mutation (G559C) [correction of G599C] associated with mild osteogenesis imperfecta and dentinogenesis imperfecta. *Arch Oral Biol* 46:459–470.
- Peng H, Zhang Y, Long Z, Zhao D, Guo Z, Xue J, Xie Z, Xiong Z, Xu X, Su W, et al. (2012) A novel splicing mutation in COL1A1 gene caused type I osteogenesis imperfecta in a Chinese family. *Gene* 502:168–171.
- Pyott SM, Tran TT, Leistritz DF, Pepin MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, et al. (2013) WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. *Am J Hum Genet* 92:590–597.
- Rauch F and Glorieux FH (2005) Osteogenesis imperfecta, current and future medical treatment. *Am J Med Genet C Semin Med Genet* 139C:31–37.
- Rauch F, Moffatt P, Cheung M, Roughley P, Lalic L, Lund AM, Ramirez N, Fahiminiya S, Majewski J and Glorieux FH (2013) Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C > T mutation in all patients. *J Med Genet* 50:21–24.
- Redford-Badwal DA, Stover ML, Valli M, McKinstry MB and Rowe DW (1996) Nuclear retention of COL1A1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta. *J Clin Invest* 97:1035–1040.
- Sarafova AP, Choi H, Forlino A, Gajko A, Cabral WA, Tosi L, Reing CM and Marini JC (1998) Three novel type I collagen mutations in osteogenesis imperfecta type IV probands are associated with discrepancies between electrophoretic migration of osteoblast and fibroblast collagen. *Hum Mutat* 11:395–403.
- Sillence DO, Senn A and Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. *J Med Genet* 16:101–116.
- Slayton RL, Deschenes SP and Willing MC (2000) Nonsense mutations in the COL1A1 gene preferentially reduce nuclear levels of mRNA but not hnRNA in osteogenesis imperfecta type I cell strains. *Matrix Biol* 19:1–9.

- Starman BJ, Eyre D, Charbonneau H, Harrylock M, Weis MA, Weiss L, Graham Jr JM and Byers pH (1989) Osteogenesis imperfecta. The position of substitution for glycine by cysteine in the triple helical domain of the pro alpha 1(I) chains of type I collagen determines the clinical phenotype. *J Clin Invest* 84:1206–1214.
- Swinnen FK, De Leenheer EM, Coucke PJ, Cremers CW and Dhooge IJ (2009) Audiometric, surgical, and genetic findings in 15 ears of patients with osteogenesis imperfecta. *Laryngoscope* 119:1171–1179.
- Valli M, Barnes AM, Gallanti A, Cabral WA, Viglio S, Weis MA, Makareeva E, Eyre D, Leikin S, Antoniazzi F, et al. (2012) Deficiency of CRTAP in non-lethal recessive osteogenesis imperfecta reduces collagen deposition into matrix. *Clin Genet* 82:453–459.
- van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M, Symoens S, Sistermans EA and Pals G (2012) EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. *Eur J Hum Genet* 20:11–19.
- Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ and Glorieux FH (2002) Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. *Bone* 31:12–18.
- Witecka J, Augusciak-Duma AM, Kruczek A, Szydlo A, Lesiak M, Krzak M, Pietrzyk JJ, Männikkö M and Sieron AL (2008) Two novel COL1A1 mutations in patients with osteogenesis imperfecta (OI) affect the stability of the collagen type I triple-helix. *J Appl Genet* 49:283–295.
- Xiao J, Cheng H, Silva T, Baum J and Brodsky B (2011) Osteogenesis imperfecta missense mutations in collagen: structural consequences of a glycine to alanine replacement at a highly charged site. *Biochemistry* 50:10771–10780.
- Xu K, Nowak I, Kirchner M and Xu Y (2008) Recombinant collagen studies link the severe conformational changes induced by osteogenesis imperfecta mutations to the disruption of a set of interchain salt bridges. *J Biol Chem* 283:34337–34344.
- Xu Z, Li Y, Zhang X, Zeng F, Yuan M, Liu M, Wang QK and Liu JY (2011) Identification and molecular characterization of two novel mutations in COL1A2 in two Chinese families with osteogenesis imperfecta. *J Genet Genomics* 38:149–156.
- Zhang ZL, Zhang H, Ke YH, Yue H, Xiao WJ, Yu JB, Gu JM, Hu WW, Wang C, He JW, et al. (2012) The identification of novel mutations in COL1A1, COL1A2, and LEPRE1 genes in Chinese patients with osteogenesis imperfecta. *J Bone Miner Metab* 30:69–77.

Internet Resources

Osteogenesis imperfecta and Ehlers-Danlos syndrome variant databases compiled of previously reported OI mutations in *COL1A1* and *COL1A2*, <http://www.le.ac.uk/ge/collagen/>; last update Mar 13, 2013.

UniProKB database, <http://www.uniprot.org/uniprot/P02452>.

ORF Finder in BLAST software suite, <http://www.ncbi.nlm.nih.gov/gorf/>.

Associate Editor: Maria Luiza Petzl-Erler

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.